Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)
LONDON, Oct. 22, 2014 /PRNewswire/ -- This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The personalized medicine (global) market is presented as follows:
• By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD, FOUNDATION MEDICINE, GENOMIC HEALTH)
• By Geography (Global, US)
• By Sub-market (Global Biomarker Market, Cancer Biomarker Market, Global Cancer Profiling Technology Market )
A wealth of financial data & business strategy information is provided including:
• Up-to-date company financials, sales & revenue figures
• Revenue and market forecasts up to 2018
• Business model strategies for diagnostic, pharmaceutical and biotechnology companies
• Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
• Comprehensive account of company product financials, portfolios & kits
SWOT, Economic & Regulatory Environment specifics include:
• Key strengths, weaknesses and threats influencing leading player position within the market
• Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
• Top fastest growing market segments and emerging opportunities
• Top pharmaceutical companies within the cancer biomarker market
• Comprehensive product portfolios, R&D activity and pipeline therapeutics
• M&A activity and future strategies of top companies
• Approved biomarker companion diagnostic tests
• High demand and Unmet Need Enhances the Global Biomarker Market
• FDA Support Increases Biomarker Development
• More Streamlined Clinical Trials
• Significant Growth of High-Impact Oncogenic Biomarker Research
• Advancements in Discovery Technologies
• Challenges of the Oncogenic Biomarker Market
• Variability of Biomarkers within Different Cancer Subtypes
• Integration of Genomics and Biomarker Diagnostics into the Healthcare System
• Ethical Considerations
This report highlights a number of significant Indian pharmacos and gives details of their operations, products, financials and business strategy.
• 23andMe
• Affymetrix
• Ambry Genetics
• Astex Pharmaceuticals
• Atossa Genetics
• BioMerieux
• CuraGen
• Celera Corporation (Quest Diagnostics)
• Celldex Therapeutics
• deCode Genetics (Amgen)
• Foundation Medicine
• Illumina
• Genelex
• Genomic Health
• Myriad
• Nodality
OriGene Technologies
• Randox
• Qiagen
Benefits of Investing in our Cutting-Edge Reports: Clients receive complementary content* with mid-level and enterprise wide licences Post-sale complementary consultation with senior expert analyst is included Use of tables and figures in your own reports and presentations is permitted Each report provides straight-talking strategic analysis & sector intelligence All reports are updated each quarter to give you the most up-to-date information WE WANT TO MAXIMIZE YOUR BUSINESS POTENTIAL * Subject to terms & conditions negotiated with Kelly Scientific Publications prior to sale
Download the full report: https://www.reportbuyer.com/product/2092773/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global--usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis-121016132.html
SOURCE ReportBuyer
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article